Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. — VialBase Research
A narrative review situating ipamorelin among GHS-class agents as a body-composition-focused adjunct in hypogonadism, while explicitly flagging that dedicated clinical evidence for ipamorelin itself is still lacking.
- Growth hormone secretagogues (GHS) — sermorelin, GHRP-2, GHRP-6, ibutamoren, and ipamorelin — are reviewed as potential adjunctive therapy for hypogonadal and eugonadal males with metabolic syndrome or subclinical hypogonadism.
- Testosterone remains the gold-standard treatment for hypogonadism, but its benefits on body composition are not consistently conserved across all patient populations.
- All GHS discussed, including ipamorelin, are described as potent GH and IGF-1 stimulators capable of meaningfully improving body composition.
- GHS are framed as potentially ameliorating hypogonadal symptoms such as fat gain and muscular atrophy alongside GH/IGF-1 stimulation.
- The authors state that clinical efficacy data for GHS remain sparse, limiting firm conclusions and highlighting the need for further investigation.
Summary
This narrative review examines the role of growth hormone secretagogues (GHS) as a complementary treatment approach for body composition changes in hypogonadal and eugonadal males with metabolic syndrome or subclinical hypogonadism. It positions GHS as a response to the limitation that testosterone, while the gold-standard hypogonadism therapy, does not consistently improve body composition across all patient populations. The GHS class surveyed includes sermorelin, GHRP-2, GHRP-6, ibutamoren, and ipamorelin, all described as potent stimulators of GH and IGF-1 secretion capable of improving body composition and addressing symptoms like fat gain and muscle atrophy. The authors are explicit that clinical efficacy data on these compounds remain limited, framing the review as identifying an area for future research rather than establishing proven benefit. Ipamorelin appears only as one of five agents discussed at the class level; no ipamorelin-specific trial data are presented.
Key Findings
- Reviews GHS (sermorelin, GHRP-2, GHRP-6, ibutamoren, ipamorelin) as a potential adjunctive therapy for hypogonadal/eugonadal males with metabolic syndrome or subclinical hypogonadism.
- Notes that testosterone, the gold-standard hypogonadism treatment, does not reliably improve body composition in all populations, motivating interest in GHS as a complement.
- Describes all discussed GHS, ipamorelin included, as potent GH and IGF-1 stimulators with potential to improve body composition and ameliorate fat gain and muscular atrophy.
- States plainly that clinical efficacy data on GHS “largely remain lacking,” limiting conclusions about real-world benefit.
- Concludes the paucity of data “does open opportunities for future investigation” rather than asserting established efficacy.
Relevance to Ipamorelin
This review discusses ipamorelin only as one of five GHS-class agents (alongside sermorelin, GHRP-2, GHRP-6, and ibutamoren) considered for improving body composition in hypogonadal males, not as a dedicated ipamorelin trial. Its value for VialBase is contextual: it frames ipamorelin’s plausible mechanism (GH/IGF-1 stimulation) within a broader clinical rationale for GHS as testosterone adjuncts, while explicitly cautioning that clinical efficacy evidence for the class remains sparse. Readers should treat this as supporting rationale for further study, not as proof of ipamorelin’s efficacy for body composition in hypogonadism.
Citation
Sinha DK, Balasubramanian A, Tatem AJ, et al. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Translational Andrology and Urology. 2020;9(Suppl 2):S149-S159. doi:10.21037/tau.2019.11.30.
See Also
- Parent compound: Ipamorelin
Save 15% with code VIALBASE
VialBase may earn a commission on partner links — never at extra cost to you. Disclosure.